Humacyte, Inc. (NASDAQ:HUMAW) Short Interest Up 614.1% in June

Humacyte, Inc. (NASDAQ:HUMAW) was the recipient of a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 24,488 shares, a growth of 614.1% from the June 15th total of 3,429 shares. Based on an average daily volume of 51,673 shares, the days-to-cover ratio is currently 0.5 days.

Humacyte Trading Down 6.2%

Shares of NASDAQ:HUMAW traded down $0.00 during midday trading on Monday, reaching $0.01. 156 shares of the company’s stock traded hands, compared to its average volume of 18,246. Humacyte has a one year low of $0.00 and a one year high of $0.60. The stock has a 50 day moving average of $0.04 and a 200 day moving average of $0.08.

About Humacyte

Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.